| MORPHOSYS AG O.N. | 82.54 / +0.54% |
| Date/Time | 03/09 / 09:13 |
| Chg. / Chg.(%) | 0.44 / +0.54% |
| Bid | 82.46 / 3 |
| Ask | 82.56 / 50 |
| Open | 82.50 |
| Previous Close | 82.10 |
| High | 82.84 |
| Low | 81.66 |
| Volume [EUR] | 765,330.74 |
| Volume [Units] | 9,312 |
| Price fixings | 114 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 82.54 |  |
9,312 |
| Cboe Europe .. | 82.58 | |
4,059 |
| TradeGate | 82.440 | |
3,082 |
| Turquoise | 81.94 | |
889 |
| London Inter.. | 82.68 | |
522 |
| Stuttgart | 82.060 | |
74 |
| Frankfurt | 82.5000 | |
30 |
| gettex | 82.400 | |
22 |
| Vienna Globa.. | 81.98 | |
0 |
| Hannover | 82.00 | |
0 |
| Berlin | 82.02 | |
0 |
| München | 82.02 | |
0 |
| Hamburg | 82.00 | |
0 |
| Düsseldorf | 82.02 | |
0 |
| Lang & Schwa.. | 82.460 |  |
|
| Nasdaq Other.. | 98.7900 |  |
20,563 |
| Cboe Europe .. | 81.90 | 128 | |
| Cboe Europe .. | 82.95 | 110 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time